Is there a "safe" dose of 7-OH? What the evidence shows

There is no established safe dose of 7-hydroxymitragynine (7-OH). The FDA has not approved it for any medical use, no clinical dosing standard exists, and the products sold over the counter vary so widely in potency that "a tablet" is not a stable or predictable unit of measurement.

7-OH is a potent opioid. The FDA's 2025 scientific assessment documented that it produces respiratory depression, physical dependence, and withdrawal symptoms consistent with classical opioids like morphine and fentanyl. The question of how much is safe has the same answer it would for any unapproved, unregulated opioid compound: there is no verified answer, and the absence of one is itself the hazard.

At a glance: the "safe dose" question

Key Takeaways

• No established safe dose of 7-OH exists. It is an unapproved, unregulated opioid compound with no clinically validated dosing framework.
• Potency and product variability make self-dosing unreliable. The same brand of product can vary significantly in actual 7-OH concentration, and labels do not reliably reflect what is inside.
• Tablet stacking is where the acute danger concentrates. Combining multiple tablets, whether at once or over a session, removes any buffer between "what worked before" and a potentially fatal dose.
• 7-OH overdose looks like opioid overdose: slowed or stopped breathing, unresponsiveness, blue lips or fingertips. Call 911 immediately and give naloxone if available.
• If use has started to feel out of control, buprenorphine-based treatment works for 7-OH dependence and is available through telehealth.

Why no safe dose exists

It is unapproved and unregulated. The FDA has not approved 7-OH for any use. In July 2025, the FDA formally recommended that the DEA restrict concentrated 7-OH products, and in July 2026 the DEA filed notices of intent to temporarily place 7-OH above a specified threshold in Schedule I. There is no approved clinical dose to reference because no such dose has ever been established through the regulatory process.

The potency data are alarming. The FDA's 2025 scientific assessment of 7-OH found that it produces respiratory depression with more than three times the potency of morphine in preclinical studies. A peer-reviewed study published in a 2025 issue of a pharmacology journal confirmed that 7-hydroxymitragynine induces significant respiratory depression comparable to morphine, and that this effect is dose-dependent and reversible with naloxone. For context, morphine is already a high-potency opioid with a narrow margin between a therapeutic dose and a dangerous one. A compound that suppresses breathing at lower doses than morphine is not one for which "just take a little" is a meaningful safety concept.

There is no protective respiratory ceiling in concentrated products. Raw kratom leaf contains mitragynine as its dominant alkaloid, and research suggests mitragynine's respiratory effects involve a ceiling in animal models, meaning increasing the dose does not proportionally increase respiratory risk beyond a point. Concentrated 7-OH products do not carry this protection. The FDA's 2025 assessment specifically identified this distinction as a core reason why concentrated products are more dangerous than leaf. More 7-OH means more respiratory risk, with no built-in limit.

The label does not tell you what is in the product. Unregulated concentrated 7-OH tablets are not subject to manufacturing standards, third-party potency verification, or labeling accuracy requirements. Analyses of commercial products have found concentrations ranging from trace amounts to near-pure 7-OH, sometimes far exceeding what a label states. What a product says it contains and what it actually contains are not the same thing.

The dangers of tablet stacking

Tablet stacking refers to taking multiple concentrated 7-OH tablets at once, or adding tablets over time as tolerance rises. It is not a technique; it is a risk pattern that describes how many people who started with one tablet end up in trouble.

Tolerance to opioids can develop within days to a few weeks of regular use. When a person feels that one tablet is no longer producing the same effect, the natural response is to take more. With a product that has no dosing standard, no ceiling effect on respiratory risk, and no accurate label, this escalation is particularly dangerous. Each additional tablet adds more opioid load to the body without the user having any reliable sense of where the overdose threshold is.

The risk multiplies significantly when 7-OH is combined with other central nervous system depressants. Alcohol, benzodiazepines, sleep aids, and muscle relaxants all suppress breathing through mechanisms that interact with opioid-mediated respiratory depression. Taking concentrated 7-OH alongside any of these substances sharply raises the risk of fatal respiratory depression, even at amounts that might not be dangerous on their own.

The Blue Ridge Poison Center at UVA Health has noted that 7-OH has a longer half-life than naloxone, which matters in an overdose setting: a person may appear to recover after naloxone is given, then experience returning respiratory depression as the naloxone wears off before the 7-OH does.

Overdose signs and what to do

A 7-OH overdose looks the same as any opioid overdose. Know the signs:

• Breathing that is very slow, shallow, or stopped entirely
• Unresponsiveness, cannot be woken by voice or touch
• Gurgling or choking sounds
• Blue or gray color to lips, fingernails, or skin
• Pinpoint (very small) pupils
• Limp body

If you see these signs:

1. Call 911 immediately. Do not wait.
2. Give naloxone (Narcan) if available. Naloxone nasal spray is available without a prescription at most pharmacies.
3. Stay with the person until emergency services arrive.
4. Because 7-OH can outlast a single dose of naloxone, give a second dose if the person does not respond within 2 to 3 minutes, and expect that hospital monitoring may be needed even after the person wakes up.

If you use concentrated 7-OH, never use alone. Having someone present who can recognize the signs and administer naloxone is one of the most meaningful ways to reduce fatal risk while you are still using.

When cutting back stops working

If any of the following sound familiar, it is worth talking to a clinician:

• Needing more of the product to feel the same effect
• Feeling sick, anxious, or unable to sleep when skipping doses
• Trying to use less and finding it harder than expected
• Use taking up more time, money, or mental space than intended

These are signs of physical dependence, not a personal failing. Concentrated 7-OH dependence follows the same physiological pattern as opioid dependence generally, and withdrawal from it can be as difficult as withdrawal from prescription opioids. That physical discomfort is one of the main reasons cutting back on one's own is so hard.

Buprenorphine/naloxone (Suboxone) is an FDA-approved medication that stabilizes opioid dependence, including dependence on 7-OH. It works by occupying the same receptors that 7-OH acts on, which prevents withdrawal and reduces cravings without producing a high. It is available through a telehealth visit in most states, often on the same day someone reaches out.

Frequently Asked Questions

Is there any amount of 7-OH that is considered safe?

No regulatory agency or clinical body has established a safe dose of 7-OH. The FDA has not approved it for any use, and no clinical trial has produced validated dosing guidance for human use. The FDA's 2025 scientific assessment documented serious opioid risks including respiratory depression, dependence, and death associated with concentrated 7-OH products. In the absence of any approved dosing framework, no amount can be characterized as clinically safe.

Why is concentrated 7-OH more dangerous than regular kratom?

Raw kratom leaf contains primarily mitragynine, which has a lower affinity for opioid receptors and, in animal research, shows a ceiling effect on respiratory depression. Concentrated 7-OH products remove that buffer. The FDA's 2025 assessment specifically identified concentrated products as a distinct risk category because 7-OH acts more powerfully at opioid receptors than mitragynine and produces dose-dependent respiratory depression without the same ceiling. The shift from leaf to extract is not a difference of degree; it is a difference in the underlying pharmacology.

Can naloxone reverse a 7-OH overdose?

Yes, but with an important caveat. Research confirms that naloxone reverses 7-OH-induced respiratory depression. However, 7-OH has a longer half-life than naloxone. A person who receives naloxone and appears to wake up may experience returning sedation and breathing problems as the naloxone wears off. This is why calling 911 is essential even after giving naloxone, and why hospital observation may be needed after apparent recovery.

What does 7-OH withdrawal feel like?

7-OH withdrawal resembles opioid withdrawal: muscle aches, sweating, nausea, diarrhea, anxiety, insomnia, and strong cravings. The severity tends to reflect how much and how long a person has been using. The UVA Blue Ridge Poison Center clinical note describes 7-OH withdrawal management as similar to opioid withdrawal management, with buprenorphine as an appropriate option for severe or persistent cases.

Can I get treatment for 7-OH dependence through telehealth?

Yes. Buprenorphine/naloxone is the standard medication for opioid use disorder and is effective for 7-OH dependence. It can be prescribed after a telehealth video visit in most states, often on the same day.